.png)
← All articlesA plateau on a GLP-1 is not a sign the medication has stopped working. It is the point where your body's appetite and energy systems have caught up with the drug, and the scale settles at a new equilibrium. In the trials that got semaglutide and tirzepatide approved, almost everyone plateaued, most of them between the first and second year, and the people who kept going did not drift back up. What matters is what happens next: whether your plan gets adjusted, or you keep doing the same thing and conclude it failed. This guide explains why the stall happens, how long the trial plateaus actually took, the seven things a provider checks before calling it a plateau, and what changes when it really is one.
Your body defends its weight. When you lose fat, hunger rises and energy expenditure falls, and both effects scale with how much you have lost. Kevin Hall's group at the National Institutes of Health modeled this feedback for diet restriction, semaglutide 2.4 mg, tirzepatide 10 mg and gastric bypass surgery in a 2024 paper in Obesity. Diet alone runs into the full force of that appetite rebound early, which is why most diets stall within months. The medications and surgery substantially weaken the appetite feedback, which is why weight keeps falling for a year or more before it levels off. But they do not switch the feedback off. At some point the drug's effect on hunger and the body's push to eat more balance each other, and the loss stops.
That balance point is the plateau. It is physiology, not willpower, and it is not a malfunction of the medication. Two things follow from that. First, a stall after a long run of steady loss is expected and should be planned for from the first visit, which is how the program at Contour Medical Clinic in Tarzana is built. Second, the plateau weight is a moving target: it depends on dose, on what you are eating, on how much muscle you have kept, and on sleep and stress. Change those inputs and the equilibrium moves.
The published trials give a realistic timeline, and it is longer than most people expect.
Three practical lessons sit inside those numbers. A real plateau on a full maintenance dose usually arrives after 12 to 18 months, not after 8 weeks. The level you plateau at depends heavily on dose, and in the tirzepatide trial the gap between 5 mg and 15 mg was about six percentage points of body weight. And holding a plateau is itself a result: the two-year semaglutide group kept 15 percent off, which almost no diet study has ever shown.
Most of the "plateaus" that come through the clinic are not plateaus at all. They are one of the following, and each has a different fix.
The FDA labels set a titration path for a reason. Semaglutide starts at 0.25 mg weekly and steps up every four weeks through 0.5, 1 and 1.7 mg to a maintenance dose of 2.4 mg, or 1.7 mg if that is what you tolerate. Tirzepatide starts at 2.5 mg and rises in 2.5 mg steps after at least four weeks on each dose, with maintenance at 5, 10 or 15 mg. The 0.25 mg and 2.5 mg starting doses are not treatment doses; they exist to settle the stomach. If your weight stalled at a low dose, you have not reached the part of the curve where the trial results happened. Your provider may simply be due to step you up.
The semaglutide label says to consider delaying a dose increase by four weeks if a step is not tolerated. Delaying is fine. Forgetting to resume is the most common reason for a stall in the first six months. If nausea or reflux is what stopped you, there are ways to manage it; see our guide to what is normal on a GLP-1 and what is not.
Both drugs are once weekly, and both labels allow a late dose within a window (for tirzepatide, within four days of the scheduled day; after that you skip and resume on schedule). Stretching a pen to save money, or injecting every nine or ten days instead of seven, lowers the average drug level and raises appetite between doses. One missed week a month is enough to flatten a loss curve.
The medication reduces hunger. It does not reduce the calories in food. As appetite quiets, people often add back things that are not driven by hunger: a drink in the evening, grazing while cooking, larger portions because the plate "felt small" for months. A one-week food log, written down rather than remembered, usually shows the drift. This is also the moment to revisit the pattern that works on these drugs: protein first at each meal, vegetables second, starch last, and nothing liquid with calories.
A meaningful share of weight lost on a GLP-1 is lean tissue if nobody protects it. A 2024 review in Diabetes Care on incretin therapy and body composition found that supervised resistance training programs longer than ten weeks add roughly three kilograms of lean mass and about 25 percent strength, and that resistance work beats endurance work for keeping muscle during fat loss. Protein targets in the same literature run 0.8 to 1.6 grams per kilogram of body weight per day, toward the upper end while losing. Muscle is the tissue that burns calories at rest; lose it and your plateau arrives earlier and higher. We cover the full approach in how to protect lean mass on a GLP-1, and an InBody body composition scan every few months shows whether the weight you are losing is fat or muscle, which the bathroom scale cannot.
Short sleep raises hunger hormones and lowers the willingness to train, and alcohol is calories that bypass the appetite signal entirely. If your stall lines up with a new job, a new baby, a bad quarter or a heavier social calendar, the plateau is downstream of that, not of the medication. Our note on using heat and cold for better sleep is a reasonable place to start, and the wellness lounge is next door to the clinic for a reason.
Thyroid, cortisol, low testosterone in men, perimenopause in women, and a handful of medications (some antidepressants, beta blockers, steroids, certain diabetes drugs) all push weight up or hold it in place. If you are doing everything right and the scale will not move, a lab panel is cheaper than another three months of guessing. Fatigue alongside the stall is a particular flag; see tired all the time: thyroid, hormones or something else. Where hormones turn out to be part of the picture, hormone care and weight loss are managed together in the same clinic.
If you are on a full maintenance dose, injecting on schedule, eating the way you were when the weight was coming off, training with resistance two or three times a week, sleeping, and labs are clean, then the stall is a true equilibrium. That is a decision point, not a failure, and the options are concrete.
Which of these is right for you is a provider decision made with your labs, your body composition trend and your history in front of them. The thing to avoid is the fifth option, which is to keep injecting the same dose, eating the same way, feeling discouraged, and quietly stopping. That is how most people lose the result they paid for.
Every patient in the medical weight loss program on Ventura Blvd gets a baseline body composition scan and labs before the first dose, and both get repeated on a schedule. That means when the scale stalls we can see whether fat is still dropping while muscle holds (which is a good month, not a plateau), whether lean mass is falling (which changes the plan before it changes the number), and whether anything in the blood work explains it. Dose changes, switches and the decision to move to maintenance are made at a review visit with a licensed provider, not by text, and the people who make those adjustments every few weeks are the ones who end up at the lower plateau. Patients come from Encino, Woodland Hills, Sherman Oaks and the rest of the San Fernando Valley for that follow-through more than for the prescription itself.
In the trials, average weight on a full maintenance dose kept falling for roughly 12 to 18 months before flattening, and the two-year semaglutide study held the result through month 24. A stall at week six or week ten is almost always a dosing, adherence or intake issue rather than a true plateau.
No. The medication is still suppressing appetite; your body's counter-regulation has risen to meet it. The evidence for that is what happens when people stop, which we cover in the maintenance article linked above: weight returns. A plateau while on the drug is the drug holding your new weight.
No. Dose increases on both drugs are tied to tolerability checks and to the four-week intervals on the label, and higher doses carry more gastrointestinal side effects. Bring the stall to your provider with your log; the dose decision takes five minutes once the other six causes above are ruled out.
Often, yes, and it is one of the most evidence-backed next steps after a plateau at the top semaglutide dose. The switch has its own titration and is a provider decision based on your history and tolerance.
Not while you stay on the medication and keep the habits that got you there; the two-year data shows the loss is held, not reversed. Weight regain is mainly a stopping problem, which is why maintenance is planned rather than improvised.
A stall on a GLP-1 is expected, usually arrives after a year or more on a full dose, and is a decision point with four real options. Before you call it a plateau, check dose, schedule, intake, muscle, sleep and labs, in that order. If you are stalled and want the plan adjusted rather than repeated, take the two-minute GLP-1 check and a provider will review where you are and what to change.
Written by: Contour Medical Clinic Editorial Team